章博士（John Zhang)在生物医学科学和大分子抗体药学工艺技术研究有超过25年的工作经验。他不但在美国大学担任过教授，从事口腔肿瘤发生治疗方面教学与系统基础研究。并在美国的大型生物制药公司（Lonza, Altria and Bio-Techne )担任资生科学家与高级管理职位。 他在生物药制造工艺技术领域逐步建立了强大的能力并且知识面非常广博。 章博士在2016年1月受邀作为高级副总裁进入中国药企工作。他成功领导了齐鲁药业集团的工艺与生产团队，完成了多个仿制单克隆抗体项目工艺开发与生产以提供临床研究所需用药。其中负责的一个工艺验证项目已经成功地投入商业性生产。
在2018-2020年期间，他去百济神州制药公司（BeiGene Ltd）为建立广州抗体工厂建设工艺团队的建设与早期自主研发项目的推进做出了重要贡献。 2020年7月，他加入了再鼎医药作为大分子药学副总裁，全面负责公司大分子药学。他负责公司大分子抗体工艺开发与担任再创苏州生物制药公司的企业负责人，组织实施生产运行，为公司自主研发研发项目提供临床用药。
由于章博士拥有广泛的生物药学方面的专业知识，所有工作的公司他都受邀提供药学相关专业知识与建议，对公司引进国外项目，提供十分重要的药学评估。
Dr. Zhang (John Zhang) has more than 25 years of working experience in biomedical sciences and Biologics. Prior to his industrial tenure positions, he used to work as a professor in university (University of Illinois at Chicago) and engaged in systematic studies in the originals and treatment of oral tumors. He also holds various senior management positions at large pharmaceutical companies in United States (Lonza, Altria and Bio-Techne). He has gradually established strong capabilities in the field of biopharmaceutical manufacturing technology and has accumulated wide range of knowledge.
Dr. Zhang returned to work as a Sr. VP of Biologics for Chinese pharmaceutical company (Qilu Pharmaceutical Group) in Jan. 2016. He successfully led the teams working on process development and manufacturing operations. Under his leadership, multiple bio-similar mAb projects have been successfully approved for clinical studies. One of leading project under his directly engaging in PCS and PV has been successfully approved for commercial manufacturing in 2019.
In 2018-2020, Dr. Zhang started his journey in Beigene Ltd as a VP of Manufacturing Technology. During his tenure at Beigene, Dr. Zhang made great contributions to the construction of BeiGene Manufacturing plant at early stage and the establishment of the Biologics CMC teams at Guangzhou Manufacturing factory. Meanwhile, he has been in charge of PD and Production team providing drug substances required for internal research projects at Suzhou Biologics Pilot Plant.
In July 2020, he joined Zai Lab as a vice president of Biologics CMC, responsible for company's Biologics process development at Shanghai site and also a head of Suzhou Biologics Pilot plant responsible for DS & DP supply for clinical studies of company's internal research and development projects. Due to his comprehensive knowledge in Biologics CMC, he has been invited to participate in the evaluations of most external Biologics projects potentially license-in for all companies he work for.